CORALAB.BO · BSE
CORAL LABORATORIES LTD.
₹598
+2.97% (+₹17.25)
Prev. close
₹580.75
Volume
1,842
As of
23 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About CORAL LABORATORIES LTD.
Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethiopia, and internationally. The company offers non-sterile products, including antibiotics/antibacterial, antifungal, gastro-intestinal drugs, antiemetic, analgesics/antipyretic/anti-inflammatory, antispasmodic, muscle relaxants, cough suppressant/expectorant, anticold, antiallergic, anti-asthmatic, cardiovascular medicines, anti-diabetic, anthelmentic, anti-protozoal/anti-amebic, antimalarial drugs, antipsychotic drugs, and thyroid products; topical, oral antiseptic, and calcium preparations; mouthwashes; nutritional, protein, and iron supplements; kits; appetizers; and other products. It also provides sterile products, such as small volume liquid, cephalosporin, betalactam, and lyophilized injectables; eye, ear, and nose drops; nasal sprays and metered dose inhalers; and large volume parenteral. In addition, the company offers various nutraceutical products, such as dietary supplements, herbal/phytochemicals, multivitamins, and nutrients, as well as OTC products. Coral Laboratories Limited was incorporated in 1994 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Girish Madanlal Dhameja
Headquarters
Mumbai
Employees
149
Website
corallab.comExchange
View on BSE ↗Key stats
Market cap
₹213.64 Cr
P/E ratio (TTM)
11.1
Dividend yield
0.34%
EPS (TTM)
₹53.78
Beta (1Y · daily vs NIFTY 50)
0.16
Beta (5Y · monthly vs NIFTY 50)
1.39
Shares float
7.92 L
EPS · quarter ended Jun 2026
₹15.08
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.3% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹96.57 Cr | ₹75.61 Cr | ₹77.89 Cr | ₹82.10 Cr | ₹113.18 Cr | ₹84.38 Cr | |
| EBITDA | ₹19.62 Cr | ₹13.03 Cr | ₹10.74 Cr | ₹22.71 Cr | ₹34.58 Cr | ₹25.42 Cr |
| ₹13.56 Cr | ₹9.05 Cr | ₹6.45 Cr | ₹15.79 Cr | ₹24.16 Cr | ₹16.38 Cr | |
| Diluted EPS | ₹37.94 | ₹25.32 | ₹18.04 | ₹44.19 | ₹67.61 | ₹45.85 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹174.35 Cr | ₹205.68 Cr | ₹229.46 Cr | ₹240.66 Cr | |
| — | — | ₹0 | ₹0 | ₹3.56 Cr | ₹4.33 Cr | |
| Stockholders' equity | — | — | ₹154.80 Cr | ₹177.50 Cr | ₹201.21 Cr | ₹209.11 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹12.67 Cr | ₹-5.46 Cr | ₹-1.22 Cr | ₹15.62 Cr | |
| Investing cash flow | — | — | ₹-2.61 Cr | ₹1.40 Cr | ₹-15.20 L | ₹-17.71 Cr |
| — | — | ₹-6.43 Cr | ₹66,000 | ₹2.71 Cr | ₹5.98 L | |
| Capital expenditure | — | — | ₹-1.95 Cr | ₹-99.10 L | ₹-2.95 Cr | ₹-23.53 Cr |
| End cash position | — | — | ₹6.13 Cr | ₹2.07 Cr | ₹3.41 Cr | ₹1.37 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| CORAL LABORATORIES LTD. | ₹205.73 Cr | ₹575.85 | 10.7 | 0.98 | 7.8% | 0.02 | -25.3% | +10.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Coral Laboratories standalone net profit rises 110.55% in the June 2026 quarter
Business Standard · 1 month ago